Efgartigimod demonstrated significant efficacy in seronegative gMG, showing improvements in Myasthenia Gravis Activities of Daily Living scores. The ADAPT SERON study is the largest to date for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback